Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ADVANCED ENZYME TECHNOLOGIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ADVANCED ENZYME TECHNOLOGIES Mar-23 |
ADCOCK INGRAM Jun-14 |
ADVANCED ENZYME TECHNOLOGIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 328 | 325 | - | |
Low | Rs | 225 | 234 | - | |
Sales per share (Unadj.) | Rs | 48.3 | 96.6 | - | |
Earnings per share (Unadj.) | Rs | 9.3 | -24.3 | - | |
Cash flow per share (Unadj.) | Rs | 12.4 | -20.2 | - | |
Dividends per share (Unadj.) | Rs | 5.00 | 0 | - | |
Avg Dividend yield | % | 1.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 110.5 | 75.8 | - | |
Shares outstanding (eoy) | m | 111.82 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.7 | 2.9 | 197.8% | |
Avg P/E ratio | x | 29.8 | -11.5 | -259.4% | |
P/CF ratio (eoy) | x | 22.3 | -13.9 | -160.8% | |
Price / Book Value ratio | x | 2.5 | 3.7 | 68.0% | |
Dividend payout | % | 53.8 | 0 | - | |
Avg Mkt Cap | Rs m | 30,939 | 47,183 | 65.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 1,148 | 2,961 | 38.8% | |
Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -957.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,406 | 16,307 | 33.2% | |
Other income | Rs m | 255 | 114 | 222.9% | |
Total revenues | Rs m | 5,661 | 16,421 | 34.5% | |
Gross profit | Rs m | 1,534 | -2,826 | -54.3% | |
Depreciation | Rs m | 350 | 704 | 49.8% | |
Interest | Rs m | 35 | 442 | 7.9% | |
Profit before tax | Rs m | 1,404 | -3,857 | -36.4% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 365 | 241 | 151.5% | |
Profit after tax | Rs m | 1,039 | -4,109 | -25.3% | |
Gross profit margin | % | 28.4 | -17.3 | -163.8% | |
Effective tax rate | % | 26.0 | -6.2 | -416.3% | |
Net profit margin | % | 19.2 | -25.2 | -76.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 7,221 | 11,944 | 60.5% | |
Current liabilities | Rs m | 776 | 6,720 | 11.5% | |
Net working cap to sales | % | 119.2 | 32.0 | 372.2% | |
Current ratio | x | 9.3 | 1.8 | 523.8% | |
Inventory Days | Days | 255 | 111 | 229.7% | |
Debtors Days | Days | 68 | 124 | 54.7% | |
Net fixed assets | Rs m | 6,884 | 6,962 | 98.9% | |
Share capital | Rs m | 224 | 76 | 295.4% | |
Net worth | Rs m | 12,351 | 12,799 | 96.5% | |
Long term debt | Rs m | 78 | 4,498 | 1.7% | |
Total assets | Rs m | 14,105 | 24,179 | 58.3% | |
Interest coverage | x | 41.4 | -7.7 | -535.0% | |
Debt to equity ratio | x | 0 | 0.4 | 1.8% | |
Sales to assets ratio | x | 0.4 | 0.7 | 56.8% | |
Return on assets | % | 7.6 | -15.2 | -50.2% | |
Return on equity | % | 8.4 | -32.1 | -26.2% | |
Return on capital | % | 11.6 | -19.8 | -58.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,404 | 1,392 | 100.8% | |
From Investments | Rs m | -2,982 | -427 | 697.7% | |
From Financial Activity | Rs m | -258 | 4,082 | -6.3% | |
Net Cashflow | Rs m | -1,709 | 5,047 | -33.9% |
Compare ADVANCED ENZYME TECHNOLOGIES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ADVANCED ENZYME TECHNOLOGIES With: DR. DATSONS LABS SUVEN PHARMACEUTICALS STRIDES PHARMA SCIENCE SEQUENT SCIENTIFIC BH.IMMUN&BIO
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.